Item 5.02. Departure of Directors or Certain Officers; Election of Directors.
On January 12, 2022, upon the recommendation of the Nominating and Corporate
Governance Committee of the Board of Directors (the "Board") of Forma
Therapeutics Holdings, Inc. (the "Company"), the Board appointed Arturo Molina,
M.D. to join the Board, effective as of such date. Dr. Molina will serve as a
Class I director until his term expires at the 2024 annual meeting of
stockholders, at which time he will stand for election by the Company's
stockholders. The Board determined that Dr. Molina is independent under the
listing standards of the Nasdaq Stock Market. Dr. Molina was also appointed to
serve on the Research and Development Committee of the Board. Effective as of
January 12, 2022, the Research and Development Committee of the Board is
composed of Dr. Molina, Timothy Clackson, Ph.D., Peter Kolchinsky, Ph.D., and
Selwyn Vickers, M.D. The composition of the Audit Committee, Compensation
Committee and the Nominating and Corporate Governance Committee remains
unchanged.
As a non-employee director, Dr. Molina will receive cash compensation and an
equity award for his Board service in accordance with the Company's Amended and
Restated Non-Employee Director Compensation Policy. Dr. Molina is not a party to
any transaction with the Company that would require disclosure under Item 404(a)
of Regulation S-K, and there are no arrangements or understandings between
Dr. Molina and any other persons pursuant to which he was selected as a
director. In addition, Dr. Molina has entered into an indemnification agreement
with the Company consistent with the form of indemnification agreement entered
into between the Company and its existing non-employee directors.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
FORMA THERAPEUTICS HOLDINGS, INC. 
